Detalles de la búsqueda
1.
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
Invest New Drugs
; 2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38842657
2.
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease.
Hepatol Res
; 2024 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400797
3.
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Hepatol Res
; 54(6): 600-605, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38234088
4.
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
J Gastroenterol Hepatol
; 39(6): 1183-1189, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494668
5.
Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.
J Viral Hepat
; 30(4): 297-302, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648382
6.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Invest New Drugs
; 41(2): 340-349, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995548
7.
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease.
BMC Gastroenterol
; 23(1): 211, 2023 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37330485
8.
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study.
Hepatol Res
; 53(5): 409-416, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36601972
9.
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hepatol Res
; 53(1): 61-71, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36070216
10.
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).
Hepatol Res
; 53(5): 383-390, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36826411
11.
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B.
Hepatol Res
; 53(1): 35-42, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117296
12.
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Invest New Drugs
; 40(2): 392-402, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34586531
13.
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Invest New Drugs
; 40(6): 1290-1297, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152108
14.
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
Dig Dis
; 40(4): 479-488, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34348262
15.
Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
J Gastroenterol Hepatol
; 37(9): 1726-1731, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35587726
16.
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
J Viral Hepat
; 28(5): 787-794, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33484033
17.
Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C.
J Med Virol
; 93(6): 3744-3751, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32890408
18.
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade.
Hepatol Res
; 51(8): 902-908, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34046984
19.
Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
J Gastroenterol Hepatol
; 36(10): 2943-2951, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34057248
20.
Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
J Gastroenterol Hepatol
; 36(10): 2960-2966, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34154037